{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:43Z","timestamp":1793766463166,"version":"4.6.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102643","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:42:06Z","timestamp":1786059726000},"page":"102643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Why Has Prostate Cancer Research Lagged Behind? Advocacy, Biology, and the Road Ahead"],"prefix":"10.1016","volume":"24","author":[{"given":"Gabriel Victor Pimentel","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-0345","authenticated-orcid":false,"given":"Marvin Paulo","family":"Lins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2026.102643_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2026.102643_bib0002","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/iju.15378","article-title":"Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer","volume":"31","author":"De Velasco","year":"2024","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102643_bib0003","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.ju.0000141580.30910.57","article-title":"Cell lines used in prostate cancer research: a compendium of old and new lines \u2014 part 1","volume":"173","author":"Sobel","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102643_bib0004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrc744","article-title":"Breast cancer activism: past lessons, future directions","volume":"2","author":"Lerner","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102643_bib0005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/pon.5264","article-title":"The role of masculinities in psychological and emotional help seeking by men with prostate cancer","volume":"29","author":"Goodwin","year":"2020","journal-title":"Psychooncology"},{"issue":"4","key":"10.1016\/j.clgc.2026.102643_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.7837","article-title":"Incidence, mortality, and federal research funding by cancer type in the US","volume":"9","author":"Mohindroo","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.clgc.2026.102643_bib0007","first-page":"591","article-title":"Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment","volume":"20","author":"Cheng","year":"2023","journal-title":"Cancer Biol Med"},{"issue":"5","key":"10.1016\/j.clgc.2026.102643_bib0008","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102643_bib0009","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102643_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1055826","article-title":"Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102643_bib0011","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2026.102643_bib0012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pros.24684","article-title":"Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer","volume":"84","author":"Shahait","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2026.102643_bib0013","article-title":"Spatial and maturity heterogeneity of tertiary lymphoid structures shapes immune microenvironment and progression in prostate cancer","author":"Wang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2026.102643_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241275389","article-title":"Understanding and addressing prostate cancer disparities in diagnosis, treatment, and outcomes among black men","volume":"31","author":"Murphy","year":"2024","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.clgc.2026.102643_bib0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.ju.0000141580.30910.57","article-title":"Cell lines used in prostate cancer research: a compendium of old and new lines \u2014 part 1","volume":"173","author":"Sobel","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102643_bib0016","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13690-025-01503-9","article-title":"Trend in cancer incidence in Mato Grosso and its health regions, Brazil, 2001\u20132018","volume":"83","author":"das Neves","year":"2025","journal-title":"Arch Public Health"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:55Z","timestamp":1793765815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001436"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102643","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why Has Prostate Cancer Research Lagged Behind? Advocacy, Biology, and the Road Ahead","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102643"}}